SLC5A2 and metabolic dysfunction-associated steatotic liver disease: <h4>Background</h4>Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, has demonstrated potential hepatic benefits in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), particularly among those with type 2 diabetes mellitus (T2DM).